News coverage about XOMA Corporation (NASDAQ:XOMA) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. XOMA Corporation earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.454368278494 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of XOMA Corporation (NASDAQ:XOMA) traded up $2.20 during trading on Friday, hitting $27.28. The stock had a trading volume of 219,100 shares, compared to its average volume of 148,879. The company has a debt-to-equity ratio of 3.53, a quick ratio of 3.45 and a current ratio of 3.45. XOMA Corporation has a fifty-two week low of $3.96 and a fifty-two week high of $33.00.

XOMA has been the subject of a number of analyst reports. Zacks Investment Research raised XOMA Corporation from a “sell” rating to a “buy” rating and set a $25.00 price target for the company in a report on Tuesday, October 17th. HC Wainwright set a $38.00 price objective on XOMA Corporation and gave the company a “buy” rating in a research note on Tuesday, November 14th. Finally, Wedbush restated a “hold” rating on shares of XOMA Corporation in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $30.00.

ILLEGAL ACTIVITY NOTICE: “XOMA Corporation (XOMA) Receives Daily News Sentiment Rating of 0.08” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at

In other XOMA Corporation news, SVP Thomas M. Burns sold 22,222 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $28.69, for a total transaction of $637,549.18. Following the completion of the transaction, the senior vice president now directly owns 13,538 shares of the company’s stock, valued at approximately $388,405.22. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James R. Neal sold 46,296 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.24, for a total value of $1,307,399.04. The disclosure for this sale can be found here. Insiders have sold a total of 87,069 shares of company stock worth $2,517,993 over the last quarter. Insiders own 3.02% of the company’s stock.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Insider Buying and Selling by Quarter for XOMA Corporation (NASDAQ:XOMA)

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.